Prediction of effect of interferon on chronic hepatitis C

Digestive Diseases and Sciences

Volumn 42, Issue 11, 1997, Pages 2270-2276

  Takagi, Hitoshi ^a   Takehara, Ken ^a   Shimoda, Ryuya ^a   Kakizaki, Satoru ^a   Takayama, Hisashi ^a   Abe, Takehiko ^a   Yamada, Toshihiko ^a   Hashimoto, Yoshiaki ^a   Saitoh, Shuichi ^a   Matsumoto, Tastuhiko ^a   Kojima, Akira ^a   Takezawa, Jirou ^a   Yuasa, Keiichirou ^a   Moriguchi, Mariko ^a   Sekiguchi, Tetsurou ^a   Nagamine, Takeaki ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus; Host; Hypervariable region; Interferon

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FATIGUE; FEMALE; FEVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER BIOPSY; MALE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; VIRUS HEPATITIS;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; FEMALE; FLUORESCENCE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS; TRANSAMINASES; VIRAL LOAD;

EID: 6844240881     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018866717753     Document Type: Article

References (17)

1. Preston H, Wright TL: Interferon therapy for hepatitis C. Lancet 348:973-974, 1996
2. Davis GL: Prediction of response to interferon treatment of chronic hepatitis C. J Hepatology 21:1-3, 1944
3. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S: The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 126:619-624, 1992
4. Enomoto H, Sakuma I, Asahina Y, Kurosakio M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81, 1996
5. De Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Uehlinger E: A classification of chronic hepatitis. Lancet 2:626-628, 1968
6. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435, 1981
7. Ichida F, Tsuji, T, Omata M, Ichida T, Inoue K, Yamada G, Hino K, Yokosuka O, Suzuki H: New Inuyama classification: New criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 6:112-119, 1996
8. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
9. Sambrook J, Fritsch EF, Maniatis T (eds): Cold Spring Harbor, New York, Cold Spring Harbor Laboratory, Molecular Cloning 2, 2nd ed. 1989, pp 20-21
10. Schulhof JC, Molko D, Teoule R: The final deprotection step in oligonuclentide synthesis is reduced to a mild and rapid ammonia treatment by using labile base-protecting groups. Nucl Acids Res 15:397-416, 1987
11. Hultman T, Stahl S, Hornes E, Uhlen M: Direct solid phase sequencing of genomic and plasmid DNA using magnetic heads as solid support. Nucleic Acids Res 17:4937-4946, 1989
12. Sekiya H, Kato N, Ootsuka Y, Nakazawa T, Yamauchi K, Shimotohno K: Genetic alterations of the putative envelope proteins encoding region of the hepatitis C virus in the progression to relapsed phase from acute hepatitis: Humoral immune response to hypervariable region 1. Int J Cancer 57:664-670, 1994
13. Sherman KE, Andreatta-C, Obrien-J, Gutierrez A, Harris R: hepatitis C in human immunodeficiency virus-coinfected patients: Increased variability in the hypervariable envelope coding domain. Hepatology 23:688-694, 1996
14. Weiner AJ, Geyson HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA: Immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 89:3468-3472, 1992
15. Kumar U, Nonjardino J, Thomas HC: Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 106:1072-1075, 1994
16. Zibert A, Schreier E, Roggendorf M: Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 208:653-661, 1995
17. Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T: The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. Hepatology 24:1018-1023, 1996